Tags : EMA’s Validation

Regulatory

Merck KGaA Reports EMA’s Validation of MAA for Tepotinib to

Shots: The MAA is based on a P-II VISION study assessing Tepotinib as monothx. in patients with advanced NSCLC of METex14 skipping alterations, prospectively assessed by liquid biopsy or tissue biopsy With the validation, the application is complete, and the EMA will now initiate the review procedure. Tepotinib is an oral MET inhibitor that inhibits […]Read More